Phathom Pharmaceuticals, Inc.

Consensus forecasts project an 80% reduction in losses by 2026, with the company expected to turn profitable at $116.3 million in 2027. Analysts maintain a Strong Buy consensus with an average price target of $16.40, implying over 30% upside, reflecting confidence in Phathom's improving financial trajectory.

Phathom carries an Altman Z-Score of -9.91 and a Piotroski F-Score of just 3, both signaling elevated bankruptcy risk. The company currently pays no dividends and has no record of generating profit, raising serious concerns about long-term capital adequacy and financial resilience.

With a consensus Moderate Buy to Strong Buy rating and price targets ranging from $16.40 to $24.50, analysts see substantial upside from current trading levels. Technical indicators in late 2025 showed a perfect 10/10 rating with both short- and long-term trends pointing upward, and relative strength outperforming 96% of the market.

Despite optimistic analyst targets, the stock has declined 9.10% over the last 52 weeks and exhibits high daily volatility averaging 8.25%. Technical signals also flag an overbought RSI near 77.88 and a sell signal from a pivot top, casting doubt on the sustainability of recent price gains.

Short-term technical models project a potential 125% price increase over three months, supported by rising volume alongside price, positive MACD signals, and buy indicators from both short- and long-term moving averages. The stock's trend is classified as a buy candidate with a rising trend channel intact.

The stock is characterized as high risk due to wide Bollinger Band prediction intervals and daily volatility of 8.25%. A sell signal was issued from a pivot top, and the stock remains closer to resistance than support intraday, making risk/reward unattractive for near-term positioning.